Home/Pipeline/PSG-201

PSG-201

Neuropathic Pain

Phase 1Completed

Key Facts

Indication

Neuropathic Pain

Phase

Phase 1

Status

Completed

Company

PharmaSGP

About PharmaSGP

PharmaSGP is a clinical-stage biopharmaceutical company headquartered in Germany with a strategic focus on neurological and rare disease therapeutics. The company has built a diversified pipeline of novel drug candidates, primarily in Phase 2 development, targeting conditions such as Parkinson's disease, epilepsy, and rare genetic disorders. With a public listing providing financial stability, PharmaSGP combines scientific innovation with commercial execution to address complex medical challenges in specialized therapeutic areas.

View full company profile

Therapeutic Areas

Neurology Rare Diseases Central Nervous System

Other Neuropathic Pain Drugs

Drug	Company	Phase	Status
Lyrica	Viatris	Approved	Commercial
MN-166 (ibudilast)	MediciNova	Phase 2	Active
GRC-301	Grace Therapeutics	Preclinical	Candidate Optimization